Summary of Research: Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC.
Tsuboi M, Herbst RS, John T, Kato T, Majem M, Grohé C, Wang J, Goldman JW, Lu S, de Marinis F, Shepherd FA, Lee KH, Le NT, Dechaphunkul A, Kowalski D, Bonanno L, Dómine M, Poole L, Bolanos A, Rukazenkov Y, Wu YL.
Tsuboi M, et al. Among authors: domine m.
Target Oncol. 2024 Mar;19(2):131-134. doi: 10.1007/s11523-024-01034-3. Epub 2024 Mar 11.
Target Oncol. 2024.
PMID: 38466534
Free PMC article.